


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Dasseux et al.

Serial No. : 09/865,989

Filed: May 25, 2001

For: APOLIPOPROTEIN A-I
AGONISTS AND THEIR
USE TO TREAT
DYSLIPIDEMIC DISORDERS



Group Art Unit: 1653

Examiner: to be assigned

Attorney Docket No.: 9196-019-999

REQUEST FOR CORRECTION OF OFFICIAL FILING RECEIPT

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Sir:

Applicants have received a Filing Receipt mailed January 15, 2002 and request the following correction be made:

1. Please correct the number of Total Claims filed from 1 to 40.
2. Please correct the number of Independent Claims filed from 1 to 5.
3. Please correct the amount of Filing Fee Received from \$355 to \$709.


A marked-up copy of the Filing Receipt is enclosed.

Applicants request that a corrected Filing Receipt be provided reflecting the above changes. This request is accompanied by a Preliminary Amendment and a Fee Transmittal Sheet.

We believe that no additional fee is required with this request, however, if it is found that a fee is necessary, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: March 15, 2002


42,983
Rahul Pathak (Reg No.)
for Laura A. Coruzzi (Reg. No. 30,742)
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20230
WWW.USPTO.GOV

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/865,989 ✓	05/25/2001 ✓	1653 ✓	355 ✓	9196-019-999 ✓	11 ✓	1 ✓	1 ✓

CONFIRMATION NO. 6407 ✓

FILING RECEIPT



OC000000007312603

24341
Pennie & Edmonds, LLP
3300 Hillview Avenue
Palo Alto, CA 94304

RECEIVED RECORDS

JAN 30 2002
RPP/EXH
& DOCKETING CA OFFICE

Date Mailed: 01/15/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

- ✓ Jean-Louis Dasseux, Mannheim, GERMANY;
- ✓ Renate Sekul, Ladenburg, GERMANY;
- ✓ Klaus Buttner, Epfenbach, GERMANY;
- ✓ Isabelle Cornut, Edingen-Neckarhausen, GERMANY;
- ✓ Gunther Metz, Edingen-Neckarhausen, GERMANY;

Assignment For Published Patent Application

Esperion Therapeutics, Inc.;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/465,719 12/17/1999 PAT 6,265,377 ✓

Foreign Applications

If Required, Foreign Filing License Granted 01/15/2002

Projected Publication Date: 04/25/2002

Non-Publication Request: No

Early Publication Request: No


** SMALL ENTITY ** ✓

Title

Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Preliminary Class

514



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



EXPRESS MAIL NO.: EL 452 482 627 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dasseux et al.

TECH CENTER 1600/2900

MAR 28 2002

RECEIVED

Application No.: 09/865,989

Group Art Unit: 1653

Filed: May 25, 2001

Examiner: To be assigned

For: APOLIPOPROTEIN A-I AGONISTS AND
THEIR USE TO TREAT DYSLIPIDEMIC
DISORDERS

Attorney Docket No.: 9196-019-999

FEE TRANSMITTAL SHEET

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying Preliminary Amendment of even date herewith concerning the above-identified application has been estimated to be \$404.

The claim amendment fee has been estimated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		SMALL ENTITY			OTHER THAN A SMALL ENTITY	
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO PREVIOUSLY PAID FOR		PRESENT EXTRA		RATE	ADDIT. FEE	OR	RATE	ADDIT. FEE
TOTAL	40	MINUS	20	=	20	× 9	\$ 180.00	×	18	\$
INDEP.	05	MINUS	03	=	2	× 42	\$ 84.00	×	84	\$
<input checked="" type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM						140	\$ 140.00		280	\$
						TOTAL	\$ 404.00	OR	TOTAL	\$

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Rahul Pathak (Reg. No. 42,983)
for Laura A. Coruzzi (Reg. No. 30,742)
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, N.Y. 10036-2711